Keryx announces positive interim results for mid stage trial drug for diabetic nephropathy treatment

Keryx Biopharmaceuticals (KERX) Announces Positive Interim Results From Phase 2 Clinical Study For KRX-101 (Sulodexide Gelcaps) For Treatment Of Diabetic Nephropathy.

Around 40% of diabetic patients progress to diabetic nephropathy. So far the progression can be delayed by tight blood sugar control etc. However there is no known cure.

In the Phase II study, 24 percent of the patients receiving a 200 milligram or 400 milligram dose of sulodexide gelcaps for six months had “therapeutic success,” compared with 13 percent of those patients receiving a placebo.

Therapeutic success is defined as conversion from microalbuminuria to normoalbuminuria when there is at least a 25 percent reduction in microalbuminuria or at least a 50 percent reduction in albumin/creatinine ratio level.

Link